Upfront Chromatography Announces Development Agreement with Cangene Corporation

Published: Mar 05, 2008

Copenhagen, March 3rd, 2008 - Upfront Chromatography A/S, the world’s leading developer of customised industrial-scale protein chromatography processes, has entered into an agreement with Cangene Corporation to develop a high-yield process for the isolation of human and equine IgG directly from blood plasma. Initial testing has demonstrated the successful capture of IgG from plasma using Upfront’s proprietary Rhobust™ processing platform. The project will incorporate a process-development and scale-up phase in order to produce material suitable for clinical trials and to determine the compatibility with Cangene’s manufacturing processes.

The implementation of Upfront’s Rhobust platform has the potential to minimise the process steps required for the isolation of IgG from blood plasma, and maximise yield and plant capacities at Cangene’s multi-product facilities.

“It is always exciting to investigate new technologies that may improve existing processes, and I look forward to seeing how Upfront’s Rhobust platform might be able to streamline our IgG processing and potentially increase product yield,” said Bill Bees, Senior Vice President, Operations, at Cangene. “Initial test results have been very promising. The Upfront team has demonstrated dedication and expertise that gives me confidence in their ability to optimise the integration of their technology with the type of process we use”.

Allan Lihme, Technical Director of Upfront Chromatography commented: “The Rhobust processing platform is adaptable to almost any process, and has the flexibility to be integrated into existing systems. Our technology is a great match for Cangene’s requirements, being designed to enable the purification of active proteins directly from blood plasma without the need for prior filtration”.

About Rhobust™ Processing Platform

The Rhobust universal processing platform from Upfront Chromatography enables customers to efficiently capture and purify monoclonal antibodies, therapeutic proteins and other biomolecules directly from blood plasma or bioreactors, without the need for prior filtration.

Selection of proprietary mixed mode ligand chemistry enables efficient control of the capture and release of target molecules by simple changes of pH, which can be readily implemented in large-scale production facilities and maintain biological activity of the product. Mixed mode ligands are selected for their suitability for industrial processing, in particular their stability during high temperature cleaning with 1M NaOH, low toxicity, and very low leakage from adsorbent.

About Upfront Chromatography:

Upfront Chromatography A/S develops and manufactures innovative products and technologies for extraction and recovery of biotherapeutics, functional biomolecules, macromolecular complexes, and even living cells, directly from bioreactors and industrial side-streams.

For customised separation services, Upfront offers access to its proprietary Rhobust™, universal process platform combined with extensive technical and regulatory support. From a feasibility study to commissioning of the final installation, Upfront works with its customers to develop adsorbents, ligand chemistry, columns and other hardware to optimise process performance. Upfront are currently developing the world’s largest chromatography system.

Upfront’s research, development and ISO9001-compliant manufacturing facility is situated in Copenhagen, Denmark. Please visit: www.upfront-dk.com

About Cangene Corporation

Cangene is one of Canada's largest and earliest biopharmaceutical companies. It was founded in 1984 and is headquartered in Winnipeg, Manitoba. It uses patented manufacturing processes to produce plasma-derived and recombinant therapeutic proteins. Cangene has three FDA and Health Canada-approved products and a fourth that has been approved in Canada only. One of its recombinant protein products has received an approvable letter from the FDA and another has been submitted for regulatory review in Canada. In addition, the Company has several more products in development at various stages. Three of Cangene's products have been accepted into the U.S. Strategic National Stockpile - botulism antitoxin, anthrax immune globulin and vaccinia immune globulin, a product used to counteract certain complications arising from smallpox vaccination.

Capitalizing on its drug manufacturing expertise, Cangene also operates a significant contract research and manufacturing business using its Winnipeg facilities and the resources of Baltimore, Maryland-based Chesapeake Biological Laboratories, Inc. (a wholly owned subsidiary). An expansion in 2006 at the Winnipeg location increased the Company's capacity to fractionate plasma to accommodate the growing manufacturing requirements. Cangene's website, www.cangene.com, includes product and investor information, including past news releases. Chesapeake's website is www.cblinc.com.

For further information, please contact:

At Upfront Chromatography: Rob Noel, Business Development Manager rn@upfront-dk.com

Natalya Clark Marketing/PR Manager nac@upfront-dk.com

At College Hill Ben Routley, Account Manager ben.routley@collegehill.com T: +44 (0) 1260 296500

Back to news